Startup from George Church’s lab raises $75M to develop ‘supercell’ medicines

A new company born out of research done by top Harvard genetic scientist George Church is promising to “revolutionize cell therapy.”

The company, GC Therapeutics, announced its launch Thursday with $75 million in financing from investors including Cormorant Asset Management and Mubadala Capital. Its board and list of advisers includes John Maraganore, the founding CEO of Alnylam Pharmaceuticals, and Steve Paul, the former CEO of Karuna Therapeutics, along with three executives representing investors.